A Florida House subcommittee approved a bill that would require pharmacists to alert prescribing doctors when they substitute a biosimilar drug for a brand-name biologic drug and to keep records of biosimilar substitutions for four or more years. Opponents, including pharmacy benefit managers, pharmacists and some drugmakers, say the bill would stifle innovation, deny patients needed care and keep drug costs high.

Related Summaries